The challenge
In biotechnology, technical novelty creates value only when it is translated into credible products, clear customer workflows, and manageable development paths.
Fareban Holdings • Public Overview
An IP-led reproductive-technology portfolio with focused operating companies.
Fareban Holdings is a biotechnology holding company that originates, protects, and licenses intellectual property to three focused operating companies: Aevrium Biosciences, Nevulium Biosystems, and Kura Biopreservation. The portfolio is structured to support a staged path to value creation: Aevrium as a near-term fertility-lab workflow opportunity, Nevulium as a larger-scale prenatal and blood-workflow opportunity, and Kura as a longer-horizon preservation platform.
This page provides a non-confidential company overview. Detailed technical, diligence, and investment materials are available only through appropriate confidential channels.
Licensed operating companies connected to Fareban Holdings:
Aevrium Biosciences
Nevulium Biosystems
Kura Biopreservation
Vision / Problem-Solution
One parent platform, three focused routes to value creation.
Fareban addresses a familiar biotechnology company-formation challenge: valuable IP is easier to evaluate when each opportunity has a clear market focus and execution path. Fareban separates parent-level IP stewardship from OpCo-level execution so each business can be reviewed on its workflow fit, development requirements, commercial pathway, and strategic potential.
The Fareban structure
Fareban licenses IP to OpCos with distinct execution paths: Aevrium for fertility-lab workflow, Nevulium for prenatal and blood-workflow qualification, and Kura for preservation and biologic-storage optionality.
The investor lens
The portfolio presents a staged set of differentiated opportunities, each with its own development profile and strategic pathway.
Licensed Operating Companies
Three OpCos, each with a focused market wedge.
The portfolio is organized around practical sequencing: begin with an accessible fertility-lab workflow opportunity, build toward larger platform opportunities, and preserve longer-horizon option value.
1
Near-term workflow wedge
Aevrium Biosciences
Aevrium is focused on reproductive microfluidics and fertility-lab workflow opportunities. Aevrium emphasizes productization, workflow fit, and repeatable laboratory use cases.
- Fertility-lab workflow and companion-tool positioning.
- Potential adjacency into broader IVF workflow, andrology tooling, animal breeding, and research-lab selection systems.
- The clearest entry point for early portfolio credibility.
IP relationship: licensed from Fareban Holdings.
2
Larger scale opportunity
Nevulium Biosystems
Nevulium is focused on prenatal and blood-workflow qualification opportunities. Nevulium reflects a larger strategic opportunity within technically, clinically, and regulatorily sensitive whole-blood and prenatal contexts.
- Qualification, triage, adequacy, and burden-reduction framing.
- Potential adjacency into adjacent blood-based molecular workflows.
- Longer-range potential in closed sample-preparation architectures.
IP relationship: licensed from Fareban Holdings.
3
Strategic option value
Kura Biopreservation
Kura is focused on embryo and biologic-preservation opportunities, including non-cryogenic preservation concepts. Kura emphasizes strategic optionality in preservation and biologic-storage applications.
- Preservation, transport, recovery, and logistics framing.
- Potential adjacency into biobanking automation and specialty biologic storage.
- Longer-horizon opportunity with higher validation and adoption requirements.
IP relationship: licensed from Fareban Holdings.
Market Context
Large reproductive-health and molecular-workflow categories.
Fareban uses third-party public market references as directional context for IVF devices and consumables, NIPT, cryopreservation, and adjacent markets. These references are provided for context only and are not forecasts, guarantees, or indications of expected revenue.
Important note: Market sizes, rankings, and sequencing language are illustrative and subject to revision. They are not financial projections, investment-return estimates, clinical claims, or assurances that any product will be approved, adopted, reimbursed, or commercialized.
Aevrium market context
Fertility clinics already perform specialized laboratory workflows. Aevrium is positioned around potential workflow enhancement and consumable or companion-tool use cases.
Nevulium market context
Prenatal and blood-based molecular workflows are large and clinically sensitive. Nevulium is positioned around qualification and sample-workflow logic, not diagnostic-performance claims.
Kura market context
Cryogenic preservation is deeply entrenched. Kura is positioned as a longer-horizon preservation opportunity that would require careful validation before clinical or commercial adoption.
Business Model
Parent-platform economics with OpCo-level execution.
Fareban Holdings is structured to preserve parent-level strategic value while allowing each licensed operating company to develop its own market, partnership, financing, and diligence pathway.
IP licensing
Fareban licenses intellectual property to Aevrium Biosciences, Nevulium Biosystems, and Kura Biopreservation under company-specific operating pathways.
Company formation
Each OpCo can maintain a distinct partner strategy, development plan, diligence pathway, and commercialization strategy.
Investor materials by request
Investor decks, diligence files, and technical materials are provided selectively, subject to applicable securities, confidentiality, and disclosure controls.
Strategic pathways
The structure may support financing, licensing, collaboration, joint development, or commercial partnership discussions at the OpCo or platform level.
IP Foundation
A protected portfolio mapped to company-specific value stories.
Fareban describes the existence and strategic organization of its IP portfolio at a high level while preserving confidential technical detail, patent strategy, experimental data, and trade-secret implementation details.
Aevrium IP focus
High-level reproductive microfluidics, gamete-selection, and fertility-lab workflow architecture.
Nevulium IP focus
High-level prenatal and whole-blood sample-workflow qualification, adequacy, and closed sample-preparation logic.
Kura IP focus
High-level embryo and biologic preservation, storage, transport, recovery, and controlled-exchange concepts.
Progress & Diligence Path
Clear sequencing for investor and partner conversations.
Investor and partner inquiries begin with email or the request form. Qualified inquiries may receive confidential materials or private meeting options only after review.
Established
Portfolio architecture
Fareban Holdings positioned as the IP-led parent platform for three licensed biotechnology operating companies.
Aligned
Investor sequencing
Aevrium leads the near-term workflow narrative, Nevulium expands the scale narrative, and Kura contributes differentiated preservation optionality.
Protected
IP portfolio organized by OpCo
Portfolio descriptions remain high-level and non-enabling. Confidential decks, technical files, financial terms, projections, diligence materials, and scheduling links are not released automatically from the public website.
Next
Screened investor and strategic partner engagement
Fareban reviews investor and partner inquiries before sharing confidential materials or private meeting options.
Legal & Disclosure
Responsible disclosure for public audiences.
This website provides a non-confidential company overview. It does not include investment terms, product-performance claims, or direct public access to diligence materials, and market and development statements are informational and subject to risk.
No securities offering
This website does not constitute an offer to sell or a solicitation of an offer to buy securities. Any investment opportunity, if made available, would be offered only through appropriate documents and channels, subject to applicable law.
Forward-looking information
Statements about development plans, market opportunities, partnerships, commercialization, validation, IP strategy, or future outcomes are forward-looking and subject to substantial uncertainty.
No clinical, regulatory, or performance claims
Nothing on this website states or implies that any Fareban-related product is approved, cleared, clinically validated, commercially available, or suitable for any specific clinical use.
IP and confidentiality
Portfolio descriptions are intentionally non-enabling. Technical details, patent materials, trade secrets, and diligence materials are available only through appropriate confidential channels.
Investor & Partner Access
Interested in Fareban’s portfolio strategy?
Prospective investors and strategic partners may contact Fareban by email or submit a request for investor materials. Qualified inquiries may receive confidential materials or private meeting options only after review. Calendly or other private scheduling links are shared only after screening.
Contact
Investor, strategic, and partnership discussions.
Fareban uses an email-first intake pathway for investor and partner inquiries. The public website does not automatically release confidential materials, diligence files, financial terms, projections, or scheduling links.
Investor Relations
For investor materials requests, financing conversations, and diligence introductions.
General Inquiries
For general corporate inquiries, introductions, and non-investor correspondence.
Strategic Partnerships
For OpCo-level partnerships, licensing, validation pathways, and commercialization discussions.
Request Investor Materials
Investor inquiry form
Investors and strategic parties may request information using the form below or by emailing investors@farebanholdings.com. Submissions are reviewed before any confidential materials, diligence files, financial terms, projections, technical materials, or private scheduling links are shared.
Information basis
This overview reflects Fareban’s current portfolio materials and company-prepared market framing. Market references are directional context from third-party sources and have not been independently verified on this page. Fareban may update this site as product, patent, regulatory, fundraising, and corporate details evolve.